|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
159,210,000 |
Market
Cap: |
1.34(B) |
Last
Volume: |
2,204,422 |
Avg
Vol: |
2,183,785 |
52
Week Range: |
$3.36 - $8.83 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 346 |
Guru Rank Value : 6 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Amneal Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company engaging in developing, manufacturing, marketing and distributing generic and branded pharmaceutical products across an array of dosage forms and therapeutic areas. Co. has three reportable segments: Generics, which includes various product families covering a range of dosage forms and delivery systems; Specialty, which is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders; and AvKARE, which provides pharmaceuticals, medical and surgical products, and services.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hsu Larry |
Director |
|
2015-03-31 |
4 |
A |
$0.00 |
$0 |
I/I |
73,560 |
2,618,860 |
|
- |
|
Hsu Larry |
Director |
|
2015-03-31 |
4 |
D |
$0.00 |
$0 |
I/I |
(73,560) |
209,337 |
|
- |
|
Hsu Larry |
Director |
|
2015-03-25 |
4 |
OE |
$5.06 |
$685,555 |
I/I |
73,500 |
282,897 |
|
- |
|
Hsu Larry |
Director |
|
2015-03-02 |
4 |
A |
$0.00 |
$0 |
I/I |
254,417 |
2,545,300 |
|
- |
|
Hsu Larry |
Director |
|
2015-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(254,417) |
55,151 |
|
- |
|
Nestor Michael |
President, Impax Pharm. |
|
2015-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
126,466 |
|
- |
|
Reasons Bryan M. |
Chief Financial Officer |
|
2015-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
74,746 |
|
- |
|
Wilkinson George Fred |
Chief Executive Officer |
|
2015-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
68,000 |
573,919 |
|
- |
|
Schlossberg Mark A |
SVP and General Counsel |
|
2015-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
95,205 |
|
- |
|
Nornhold Jeffrey |
SVP, Technical Operations |
|
2015-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
73,209 |
|
- |
|
Hsu Larry |
Director |
|
2014-11-07 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,725 |
2,290,883 |
|
- |
|
Hsu Larry |
Director |
|
2014-11-06 |
4 |
GD |
$0.00 |
$0 |
I/I |
17,050 |
2,292,608 |
|
- |
|
Wilkinson George Fred |
Chief Executive Officer |
|
2014-10-29 |
4 |
D |
$28.19 |
$537,893 |
D/D |
(19,081) |
505,919 |
|
- |
|
Hsu Larry |
Director |
|
2014-10-29 |
4 |
D |
$28.19 |
$51,503 |
I/I |
(1,827) |
209,397 |
|
- |
|
Nornhold Jeffrey |
SVP, Technical Operations |
|
2014-10-28 |
4 |
D |
$27.96 |
$25,527 |
D/D |
(913) |
61,209 |
|
- |
|
Hsu Larry |
Director |
|
2014-10-28 |
4 |
D |
$27.96 |
$51,083 |
I/I |
(1,827) |
211,224 |
|
- |
|
Hsu Larry |
Director |
|
2014-10-26 |
4 |
D |
$27.80 |
$50,791 |
I/I |
(1,827) |
211,224 |
|
- |
|
Nornhold Jeffrey |
SVP, Technical Operations |
|
2014-10-26 |
4 |
D |
$27.80 |
$47,038 |
D/D |
(1,692) |
62,122 |
|
- |
|
Reasons Bryan M. |
Chief Financial Officer |
|
2014-10-26 |
4 |
D |
$27.80 |
$26,132 |
D/D |
(940) |
54,746 |
|
- |
|
Hsu Larry |
Director |
|
2014-10-25 |
4 |
D |
$27.80 |
$44,146 |
I/I |
(1,588) |
213,051 |
|
- |
|
Nornhold Jeffrey |
SVP, Technical Operations |
|
2014-10-25 |
4 |
D |
$27.80 |
$50,763 |
D/D |
(1,826) |
63,814 |
|
- |
|
Hsu Larry |
Director |
|
2014-09-30 |
4 |
OE |
$9.27 |
$213,210 |
I/I |
23,000 |
214,639 |
|
- |
|
Hsu Larry |
Director |
|
2014-09-09 |
4 |
OE |
$14.90 |
$447,000 |
I/I |
30,000 |
191,639 |
|
- |
|
Schlossberg Mark A |
SVP and General Counsel |
|
2014-07-08 |
4 |
D |
$28.80 |
$81,187 |
D/D |
(2,819) |
75,205 |
|
- |
|
Hsu Larry |
Director |
|
2014-06-06 |
4 |
S |
$28.52 |
$1,425,955 |
D/D |
(50,000) |
309,568 |
|
- |
|
180 Records found
|
|
Page 7 of 8 |
|
|